The Texas Interprofessional Pharmacogenomics (IPGx)

Launched by TEXAS A&M UNIVERSITY · Jan 12, 2024

Keywords

ClinConnect Summary

The Texas Interprofessional Pharmacogenomics (IPGx) clinical trial is studying how taking multiple medications (known as polypharmacy) can lead to adverse drug reactions (ADRs) in patients who are at risk. The goal is to use advanced genetic testing to better understand how different medications interact with each other and how they are processed in the body. This information will help doctors make personalized recommendations about which medications might need to be changed or stopped to ensure safer treatment for patients.

To participate in this study, you must be 45 years or older and currently taking five or more medications, including over-the-counter drugs and supplements. Participants will need to provide consent, donate urine samples, and undergo a thorough health check. The study is open to all genders but excludes individuals with certain health conditions, such as recent cancer treatment, active liver disease, or those who are pregnant. If you decide to join, you will be part of an important effort to improve medication safety and effectiveness for people like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs
• • Ability to give and comprehend the consent process.
• • Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.
• • All genders.
• • Age 45 and over
• Exclusion Criteria:
• • Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
• • Admitted to hospice.
• • Patient has ever been diagnosed with Hepatitis B or C.
• • Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score \>10, ALT or AST \>100U/L or an AST/ALT ratio \>2
• • Patients taking imidazole antifungal medication.
• • Declines to participate or interact with staff/share their medical status.
• • A diagnosis of Alzheimer's disease
• • Pregnant patients will be excluded
• • Unable/unwilling to consent.
• • Unable to verbally communicate and comprehend English/Spanish language.